ArticleDrug and alcohol dependence2021
Maternal opioid exposure, neonatal abstinence syndrome, and infant healthcare utilization: A retrospective cohort analysis.
Article in Drug and alcohol dependence, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- The Impact of Remoteness on the Outcomes of Children With Prenatal Drug Exposure: A Population-Based Cohort Study.Journal of paediatrics and child health · 2026Article
- Preventive Care Uptake and Long-Term Healthcare Use Among Children with Fetal Opioid Exposure in Ontario, Canada: A Population-Based Retrospective Cohort Study.International journal of population data science · 2026Article
- Well-Child Visits and Immunization Encounters in South Carolina Medicaid: A 3-Year Retrospective Comparison Between Rural and Urban Children with a History of Neonatal Opioid Withdrawal Syndrome, 2006-2014.Healthcare (Basel, Switzerland) · 2025Article
- Advances in animal models of prenatal opioid exposure.Trends in neurosciences · 2024Review
- Neonatal Abstinence Signs during Treatment: Trajectory, Resurgence and Heterogeneity.Children (Basel, Switzerland) · 2024Article
- Prenatal opioid exposure and well-child care in the first 2 years of life: population-based cohort study.Archives of disease in childhood · 2023Article
- Neonatal Abstinence Syndrome in Infants with Prenatal Exposure to Methadone versus Buprenorphine.Children (Basel, Switzerland) · 2023Article
- Pediatric Primary Care Diagnoses Among Children with Intrauterine Opioid Exposure.Journal of health care for the poor and underserved · 2023Article
- Suboxone: History, controversy, and open questions.Frontiers in psychiatry · 2022Review
- Priorities for Well Child Care of Families Affected by Parental Opioid Use Disorder.Journal of addiction medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundWe sought to describe healthcare utilization of infants by maternal opioid exposure and neonatal abstinence syndrome (NAS) status.
methodsA longitudinal cohort of 81,833 maternal-infant dyads were identified from Oregon's 2008-2012 linked birth certificate and Medicaid eligibility and claims data. Chi-square tests compared term infants (≥37 weeks of gestational age) by maternal opioid exposure, defined using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes or prescription fills, and NAS, defined using ICD-9-CM codes, such that infants were categorized as Opioid+/ NAS+, Opioid+/NAS-, Opioid-/NAS+, and Opioid-/NAS-. Modified Poisson regression was used to calculate adjusted risk ratios (aRR) and 95 % confidence intervals (CI) for healthcare utilization for each infant group compared to Opioid-/NAS- infants.
resultsThe prevalence of documented maternal opioid exposure was 123.1 per 1000 dyads and NAS incidence was 5.8 per 1000 dyads. Compared to Opioid-/NAS- infants, infants with maternal opioid exposures were more likely to be hospitalized within 4 weeks (Opioid+/ NAS+: [aRR: 4.7; 95 % CI: 4.3-5.1]; Opioid+/ NAS-: [aRR: 3.7; 95 %CI: 3.1-4.5]) and a year after birth (Opioid+/ NAS+: [aRR: 3.7; 95 %CI: 3.4-4.0]; Opioid+/ NAS-: [aRR: 2.8; 95 %CI: 2.3-3.4]). Infants with maternal opioid exposure and/or NAS were more likely than Opioid-/NAS- infants to have ≥2 sick visits and any ED visits in the year after birth.
conclusionsInfants with NAS and/or maternal opioid exposure had greater healthcare utilization than infants without NAS or opioid exposure. Efforts to mitigate future hospitalization risk and encourage participation in preventative services within the first year of life may improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.